Neumora Therapeutics, Inc. — All Filings
226 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
8-A12B
8-K
8-K/A
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
POSASR
PRE 14A
S-1
S-1/A
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| DEF 14A | DEF 14A | 0000950170-25-060084 | Apr 29, 2025 | May 28, 2025 |
| 8-K/A | 8-K/A | 0000950170-25-053303 | Apr 11, 2025 | Feb 13, 2025 |
| PRE 14A | PRE 14A | 0000950170-25-053346 | Apr 11, 2025 | May 28, 2025 |
| EFFECT | — | 9999999995-25-000791 | Mar 26, 2025 | — |
| 144 | — | 0001968582-25-000180 | Mar 12, 2025 | — |
| POS AM | POS AM | 0001193125-25-044183 | Mar 3, 2025 | — |
| 8-K | 8-K | 0000950170-25-030396 | Mar 3, 2025 | — |
| S-8 | S-8 | 0001193125-25-044187 | Mar 3, 2025 | — |
| POSASR | POSASR | 0001193125-25-043400 | Mar 3, 2025 | — |
| 10-K | 10-K | 0000950170-25-030401 | Mar 3, 2025 | Dec 31, 2024 |
| 8-K/A | 8-K/A | 0001193125-25-031974 | Feb 21, 2025 | Feb 13, 2025 |
| 4 | — | 0001610717-25-000030 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | — | 0001610717-25-000029 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | — | 0001610717-25-000031 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | — | 0001610717-25-000028 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | — | 0001610717-25-000027 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-022317 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022318 | Feb 18, 2025 | Feb 13, 2025 |
| 144 | — | 0001964306-25-000080 | Feb 18, 2025 | — |
| 4 | 4 | 0000950170-25-022316 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022319 | Feb 18, 2025 | Feb 13, 2025 |
| 144 | — | 0001964306-25-000081 | Feb 18, 2025 | — |
| 4 | 4 | 0000950170-25-022325 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022321 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022326 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022320 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022322 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022327 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | 4 | 0000950170-25-022323 | Feb 18, 2025 | Feb 13, 2025 |
| 144 | — | 0001964306-25-000075 | Feb 18, 2025 | — |
| 144 | — | 0001964306-25-000076 | Feb 18, 2025 | — |
| 144 | — | 0001964306-25-000077 | Feb 18, 2025 | — |
| 144 | — | 0001964306-25-000078 | Feb 18, 2025 | — |
| 144 | — | 0001964306-25-000079 | Feb 18, 2025 | — |
| 8-K | 8-K | 0001193125-25-026156 | Feb 13, 2025 | — |
| SCHEDULE 13G/A | — | 0000950170-25-019939 | Feb 13, 2025 | — |
| 8-K | 8-K | 0001193125-25-004999 | Jan 13, 2025 | — |
| 8-K | 8-K | 0001193125-25-000084 | Jan 2, 2025 | — |
| 4 | — | 0001610717-24-000555 | Dec 27, 2024 | — |
| SC 13D/A | ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D/A(#2) | 0001072613-24-000899 | Nov 22, 2024 | — |
| 8-K | 8-K | 0000950170-24-124563 | Nov 12, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-125437 | Nov 12, 2024 | Sep 30, 2024 |
| SC 13G | — | 0001493152-24-044786 | Nov 12, 2024 | — |
| 4 | — | 0001610717-24-000511 | Oct 18, 2024 | Oct 17, 2024 |
| 144 | — | 0001964306-24-000383 | Oct 18, 2024 | — |
| 144 | — | 0001964306-24-000382 | Oct 17, 2024 | — |
| 4 | — | 0001610717-24-000505 | Oct 11, 2024 | Oct 9, 2024 |
| 144 | — | 0001964306-24-000376 | Oct 10, 2024 | — |
| 144 | — | 0001964306-24-000375 | Oct 9, 2024 | — |
| S-3ASR | S-3ASR | 0001193125-24-230348 | Oct 1, 2024 | — |